ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
19 announcements with these filters
H1 FY27 (Apr–Sep 2026): revenue ₹29.44 Cr (+109.35% YoY), EBITDA ₹6.26 Cr (21.27% margin), PAT ₹4.73 Cr (16.06% margin). Focus on capacity expansion and product diversification.
Accretion Nutraveda released a half-year media release showing revenue up 109.35% to Rs 29.44 crore. EBITDA rose 88.03% and PAT rose 98.66%.
Accretion Nutraveda Ltd reported revenue from operations of ₹29.4 Cr (+108.5% YoY) and net profit of ₹4.7 Cr (+95.8% YoY) for H1 FY27.
Accretion Nutraveda's quarterly shareholding pattern shows promoters holding 73.48%. The routine filing reports no corporate action or event value.
Accretion Nutraveda will hold a board meeting on 31 October 2026 to consider unaudited financial results for the half year ended September 2026. The intimation is a prior notice under Regulation 29.
Accretion Nutraveda Limited announced results of its postal ballot. Shareholders approved special resolutions regarding MOA alteration, borrowing limits, and various loan and guarantee authorizations.
Accretion Nutraveda Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026. This filing is a routine regulatory disclosure under SEBI LODR.
Accretion Nutraveda Limited issued a Notice of Postal Ballot to seek shareholder approval for the alteration of its Memorandum of Association. Voting concludes on October 9, 2026.
Accretion Nutraveda's board approved altering its Object Clause to include nutraceuticals and hospitals. The board also proposed increasing borrowing limits and advancing loans to related entities.
Accretion Nutraveda Limited held its 5th Annual General Meeting on 27th August, 2026, where shareholders transacted routine business, including the adoption of financial statements.
Accretion Nutraveda Limited informed shareholders of the weblink to access the FY 2025-26 Annual Report and notice for the 5th Annual General Meeting.
Accretion Nutraveda Limited has issued notice for its 5th Annual General Meeting scheduled for August 27, 2026. The meeting will address financial statement adoption and director-related resolutions.
Accretion Nutraveda Ltd submitted its Annual Report for FY 2025-26. The company also scheduled its 5th Annual General Meeting for August 27, 2026.
Accretion Nutraveda Ltd won the Global Export Excellence Award in Ayurvedic & Nutraceutical Manufacturing at the Navbharat Awards by Times Now Group. The award underscores export strength.
Accretion Nutraveda Ltd reported revenue from operations of ₹19.5 Cr (+80.6% YoY) and net profit of ₹2.7 Cr (+58.8% YoY) for H2 FY26.
Accretion Nutraveda reported annual total income of ₹33.72 Crore for FY26. The board also approved auditor re-appointments and noted two independent director resignations.
Accretion Nutraveda Ltd has scheduled a Board of Directors meeting for May 8, 2026. The board will primarily consider and approve the audited financial results for the fiscal year ended March 31, 2026.
Accretion Nutraveda Ltd clarified to BSE that recent price movements in its securities are purely market-driven. The company confirmed it has disclosed all material events under SEBI regulations and is not withholding any price-sensitive information.
Accretion Nutraveda Limited confirmed it does not fall under the 'Large Corporate' category for FY 2026-2027. Consequently, SEBI's initial disclosure requirements for fund raising by issuance of debt securities are not applicable to the company.